Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,711 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Normal Saline (0.9% NaCl) Clear all
Terminated Phase 3 Interventional Results available

A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant

NCT02547220
View directory record Official record
Conditions
Acute Antibody-Mediated Rejection (AMR)
Interventions
Cinryze®, Placebo
Biological · Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
29
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 10, 2026, 6:12 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

NCT01413503
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma
Interventions
131I-MIBG
Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
4 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Oct 10, 2026, 6:12 AM EDT
Completed Phase 2 Interventional

Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

NCT05856331
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema
Interventions
SAR447537, Zemaira
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 10, 2026, 6:12 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

NCT03403751
View directory record Official record
Conditions
Acute Kidney Injury, Peritonitis, Necrotizing Soft Tissue Infection
Interventions
Reltecimod 0.5 mg/kg, Placebo
Drug
Lead sponsor
Atox Bio Ltd
Industry
Eligibility
18 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 10, 2026, 6:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Menopause Effects on Vascular Function

NCT03236545
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
No to Low Endogenous Estrogen, Estradiol
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 10, 2026, 6:12 AM EDT
Not yet recruiting Not applicable Interventional

Intraosseous Antibiotics for Osseointegration

NCT07621094
View directory record Official record
Conditions
Osseointegration Infection
Interventions
intraosseous antibiotic delivery
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Aurora, Colorado • New York, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 10, 2026, 6:12 AM EDT
Completed Phase 1 Interventional

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

NCT02830542
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
SER-262, Placebo
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Athens, Alabama • Fountain Valley, California • La Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 10, 2026, 6:12 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)

NCT01525901
View directory record Official record
Conditions
22q13 Deletion Syndrome, Phelan-McDermid Syndrome
Interventions
Insulin-Like Growth Factor-1 (IGF-1), Normal saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
5 Years to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 10, 2026, 6:12 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

NCT03425643
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Placebo, Cisplatin, Gemcitabine, Pemetrexed
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
51
States / cities
Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 10, 2026, 6:12 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

NCT03838133
View directory record Official record
Conditions
Hallux Valgus
Interventions
TLC590, Naropin®, Normal Saline, Bupivacaine
Drug
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 10, 2026, 6:12 AM EDT
Completed Phase 3 Interventional Results available

Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®

NCT02453334
View directory record Official record
Conditions
Cancer and Chemotherapy Related Anemia
Interventions
Injectafer, Normal Saline
Drug · Other
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
29
States / cities
Corona, California • Fountain Valley, California • Riverside, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 10, 2026, 6:12 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Age Comparisons of Exercising Muscle O2 Supply in Healthy Adults: Effects of Esmolol Infusion

NCT04181606
View directory record Official record
Conditions
Aging
Interventions
Esmolol infusion, Saline infusion, Pre exercise baseline, Isometric handgrip exercise, Semi-recumbent cycling
Drug · Other
Lead sponsor
David N. Proctor, PhD
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 10, 2026, 6:12 AM EDT
Completed Phase 1 Interventional

Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood

NCT02650206
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset, Inflammation
Interventions
Victoza (liraglutide) with dietician monitoring, Placebo with dietician monitoring
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 69 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 10, 2026, 6:12 AM EDT
Recruiting Phase 2 Interventional

Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony

NCT07217899
View directory record Official record
Conditions
Blood Loss, Surgical, Blood Loss, Postoperative, Uterine Atony
Interventions
Calcium Gluconate, Saline
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 10, 2026, 6:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks

NCT01349140
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SKY0402
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 10, 2026, 6:12 AM EDT
Recruiting Phase 2 Interventional

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

NCT07219459
View directory record Official record
Conditions
Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
Interventions
Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib, Placebo Saline Infusion
Biological · Drug · Other
Lead sponsor
CatalYm GmbH
Industry
Eligibility
18 Years to 100 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 10, 2026, 6:12 AM EDT
Not listed Phase 2 Interventional

Comparison of Conservative Methods for the Treatment of Lateral Epicondylitis: A Randomized, Prospective Study

NCT01897259
View directory record Official record
Conditions
Tennis Elbow, Lateral Epicondylitis
Interventions
Placebo Injection, Physical Therapy, Corticosteroid Injections, Prolotherapy
Drug · Behavioral
Lead sponsor
Christine M. Kleinert Institute for Hand and Microsurgery
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 10, 2026, 6:12 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Trial of Oxytocin Alone Versus Oxytocin and Propranolol for the Treatment of Abnormal Labor

NCT00315913
View directory record Official record
Conditions
Dysfunctional Labor
Interventions
Propranolol, IV Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 10, 2026, 6:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

NCT00784823
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Melphalan
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 76 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 10, 2026, 6:12 AM EDT
Terminated Phase 2 Interventional Results available

Effects of Botox in Obstructed Defecation Syndrome

NCT02160288
View directory record Official record
Conditions
Obstructed Defecation Syndrome (ODS)
Interventions
Botulinum Toxin-A, Normal Saline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 10, 2026, 6:12 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

NCT00591318
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions
ceftriaxone, Normal Saline
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 10, 2026, 6:12 AM EDT
Terminated Early Phase 1 Interventional

Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

NCT02216513
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
desferrioxamine (DFO), placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Oct 10, 2026, 6:12 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

NCT01231620
View directory record Official record
Conditions
Influenza, Human
Interventions
Zanamivir, Placebo to match zanamivir, Oseltamivir, Placebo to match oseltamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 10, 2026, 6:12 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

NCT04389840
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Interventions
Dociparstat sodium, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Loxahatchee Groves, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 10, 2026, 6:12 AM EDT